Abstract: The current epidemic status, pathogenesis of rabies, the neutralizing antigen sites of RABV glycoprotein and the neutralization mechanism of the monoclonal antibodies against RABV infection were briefly described. The screening techniques, recognition sites, action mechanism and neutralization effects of almost all of the monoclonal antibodies against RABV which are currently available on the market or under development worldwide were also introduced. The paper further analyzed the problems existing in the application of the above mentioned monoclonal antibodies and the disadvantage of rabies immune globulin in the current post-exposure prophylaxis of RABV infection, including the limited blood supply, neutralization titers, the quality control and potential virus infection, which implies that the more attention should be paid to the development of full human monoclonal antibodies against RABV, especially for their neutralization efficiency and breadth. Taken together, the full human monoclonal antibodies drugs targeting the phylogroup Ⅱ/Ⅲ of glycoprotein and the cocktail targeting multiple antigenic sites are potential efficient strategy to the development of post-exposure prophylaxis of RABV infection.

Key words: rabies, rabies virus, monoclonal antibodies, neutralizing antibodies, epitope